

## Sun Pharma Advanced Research Company Limited

Regd Office: Sun Pharma Advanced Research Centre,  
Akota Road, Akota, Vadodara – 390 020. Tel. No.0265-2330815  
CIN No. : L73100GJ2006PLC047837 Web Site : www.sunpharma.in

### Statement of Unaudited Financial Results for the Quarter ended June 30, 2016

` in Lakhs

Particulars	3 Months ended			Year ended
	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	Unaudited	Audited	Unaudited	Audited
		(Refer Note 4)		
<b>Income from Operations</b>				
Income from Operations	2,148	4,117	4,344	16,128
<b>Total Income from Operations</b>	<b>2,148</b>	<b>4,117</b>	<b>4,344</b>	<b>16,128</b>
<b>Expenses</b>				
Cost of Materials Consumed	422	460	296	1,887
Employee Benefits Expense	2,037	1,591	1,365	5,660
Clinical Trials and Professional Charges	2,314	2,257	2,155	11,954
Depreciation Expense	196	196	182	758
Other Expenses	986	673	527	2,946
<b>Total Expenses</b>	<b>5,955</b>	<b>5,177</b>	<b>4,525</b>	<b>23,205</b>
<b>Profit / (Loss) from Operations before Other Income and Finance Costs</b>	<b>(3,807)</b>	<b>(1,060)</b>	<b>(181)</b>	<b>(7,077)</b>
Other Income	299	232	21	294
<b>Profit / (Loss) from ordinary activities before Finance Costs</b>	<b>(3,508)</b>	<b>(828)</b>	<b>(160)</b>	<b>(6,783)</b>
Finance Costs	133	130	5	216
<b>Profit / (Loss) from ordinary activities before Tax</b>	<b>(3,641)</b>	<b>(958)</b>	<b>(165)</b>	<b>(6,999)</b>
Tax Expense	-	-	-	-
<b>Net Profit / (Loss) for the period / year</b>	<b>(3,641)</b>	<b>(958)</b>	<b>(165)</b>	<b>(6,999)</b>
Paid-up Equity Share Capital - Face Value ` 1 each	2,469	2,367	2,367	2,367
Reserves excluding Revaluation Reserve				623
Earnings Per Share of ` 1 each – in ` (Basic and Diluted)	(1.47)*	(0.40)*	(0.07)*	(2.96)
* Not Annualised				
See accompanying Notes to the financial results				

Notes :

- 1 The above results are as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its meeting held on July 29, 2016 after being reviewed by the Audit Committee and have been subjected to a limited review by the Statutory Auditors of the Company.
- 2 The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- 3 The Company has allotted 102,04,081 (one crore two lakhs four thousand eighty one) equity shares of Rs 1/- each at a price of Rs 245/- (including premium of Rs 244/- each) per equity share aggregating Rs 25,000 lakhs to its existing equity shareholders on rights basis on April 27, 2016.
- 4 Figures for the quarter ended March 31, 2016 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2016 and the unaudited published year to date figures up to the third quarter ended December 31, 2015 which were approved by the Board of Directors and subjected to limited review by the Statutory Auditors of the Company.
- 5 Previous periods / year figures have been regrouped / rearranged, wherever necessary, to correspond to current period's presentation.

By order of the Board

Vadodara, July 29, 2016

Dilip S. Shanghvi  
Chairman and Managing Director